

Katrin Rupalla



Member of the IHI JU Science & Innovation Panel

Global Head Regulatory Affairs

Johnson & Johnson Innovative Medicines

Katrin Rupalla has extensive experience in drug development and held various leadership roles in the Pharma and biotech industry. She currently serves as the Global Head of Regulatory Affairs at J&J Innovative Medicines, USA.

Prior to joining J&J in 2023, she was an independent board member where she was responsible for governance and strategic direction of 4D Pharma, Ambrx and Zversa, overseeing one IPO and two reverse SPAC acquisitions. She also is one of the Founders and previous CEO of Ymmunobio Ltd., Switzerland a preclinical stage biotech company.

Previous senior leadership positions include Senior Vice President, Global Head Regulatory Affairs & R&D Quality, at Lundbeck SA, DK and Vice President Global Head Oncology Regulatory Science, Vice President Head China Development, and Vice President EU Regulatory Science at BMS where she led large regulatory and R&D teams.

She obtained her degree in pharmacy and her PhD in CNS Pharmacology at the Philipps University Marburg, Germany. In addition, she has an MBA from Jones International University, USA and a NED Diploma from Financial Times.